Joseph Anderson
Net worth: - $ as of 31/07/2026
Net worth: - $ as of 31/07/2026
Joseph Anderson was the founder of Arix Bioscience, established in 2015, where the title held was Chief Executive Officer & Director from 2019 to 2020.
Current jobs include Director at Abingworth Bioequities Master Fund Ltd., Non-Executive Director at Autolus Ltd. since 2016, and Partner at Sofinnova Partners SAS since 2020.
Former jobs include Independent Non-Executive Director at Amarin Corp.
Plc from 2012 to 2013, Director at Cytos Biotechnology AG from 2012 to 2016, Director at Epigenomics AG from 2012 to 2014, Non-Executive Director at Algeta ASA from 2012 to 2013, Independent Non-Executive Director at Autolus Therapeutics Plc from 2016 to 2025, Director at Cytos Ltd., Non-Executive Director at Redx Pharma Plc, Head-Strategy Unit at The Wellcome Trust Ltd. from 1990 to 1998, Head-Global Healthcare Equities at First Sentier Investors (UK) IM Ltd., Partner at Abingworth Management Ltd. from 2004 to 2015, Head-Global Healthcare & Portfolio Manager at Commonwealth Bank of Australia, Head-Strategy at Novartis Foundation, and Partner at Abingworth LLP from 2004 to 2015.
Education includes a doctorate from the University of Aston and an undergraduate degree from Queen Mary's College.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/03/2025 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Companies | Position | Start |
|---|---|---|
Abingworth Bioequities Master Fund Ltd.
Abingworth Bioequities Master Fund Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Director/Board Member | - |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Director/Board Member | 08/03/2016 |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements. | Private Equity Investor | 01/10/2020 |
| Companies | Position | End |
|---|---|---|
| AUTOLUS THERAPEUTICS PLC | Director/Board Member | 26/06/2025 |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience invests in companies located in the United Kingdom. The firm focuses on the therapeutics sector. It participates in early stage capital requirements. | Chief Executive Officer | 06/04/2020 |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops new protein drugs and innovative therapeutic concepts | Director/Board Member | 01/01/2016 |
Abingworth Management Ltd.
Abingworth Management Ltd. Investment ManagersFinance Operates as an investment firm | Corporate Officer/Principal | 01/12/2015 |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Private Equity Investor | 01/12/2015 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 19 |
|---|---|
The Wellcome Trust Ltd.
The Wellcome Trust Ltd. Investment Trusts/Mutual FundsMiscellaneous Provides welfare and charitable services | Miscellaneous |
Amarin Corp. Plc
Amarin Corp. Plc Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company which develops and commercializes therapeutics to improve cardiovascular health | Health Technology |
First Sentier Investors (UK) IM Ltd.
First Sentier Investors (UK) IM Ltd. Investment ManagersFinance Stewart Investors is an active, growth-oriented manager which seeks to preserve capital by concentrating on niche and specialist areas of the market such as real estate, infrastructure and emerging markets. They manage investments across a range of long-only equity and alternative asset classes, including Asia Pacific and Global Emerging market equities, real estate securities, infrastructure and global natural resources. The firm utilizes an investment process concentrating on absolute return and relative return. They favor a bottom-up stock selection process and focus on long-term performance. | Finance |
Abingworth Management Ltd.
Abingworth Management Ltd. Investment ManagersFinance Operates as an investment firm | Finance |
Commonwealth Bank of Australia
Commonwealth Bank of Australia Major BanksFinance Provides retail and commercial banking services | Finance |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Finance |
Cytos Biotechnology AG
Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Discovers and develops new protein drugs and innovative therapeutic concepts | Commercial Services |
Epigenomics AG
Epigenomics AG Medical SpecialtiesHealth Technology Engages in the development and commercialization of in vitro diagnostic tests for cancer | Health Technology |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners invests in companies located in the United States, France and Europe. The firm targets companies operating in the fields of life sciences and technology sectors. It provides financing for seed and early stage capital requirements. | Finance |
University of Aston
University of Aston Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Algeta ASA
Algeta ASA Pharmaceuticals: MajorHealth Technology Engages in the development of products for the treatment of cancer | Health Technology |
Cytos Ltd. | |
Queen Mary's College
Queen Mary's College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Abingworth Bioequities Master Fund Ltd.
Abingworth Bioequities Master Fund Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Redx Pharma Plc
Redx Pharma Plc Pharmaceuticals: MajorHealth Technology Discovers and develops novel, small molecule & targeted therapeutics for treatment of cancer and fibrotic disease | Health Technology |
Autolus Ltd.
Autolus Ltd. BiotechnologyHealth Technology Provides biopharmaceutical services | Health Technology |
Novartis Foundation
Novartis Foundation Miscellaneous Commercial ServicesCommercial Services Operates as a nonprofit foundation that improves urban population health through data-driven, AI-enabled initiatives, multisector partnerships and innovative health system transformation | Commercial Services |
Autolus Therapeutics Plc
Autolus Therapeutics Plc Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of gene therapies | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience invests in companies located in the United Kingdom. The firm focuses on the therapeutics sector. It participates in early stage capital requirements. | Finance |
Select your edition
All financial news and data tailored to specific country editions